Grufity logoGrufity logo

Cerus Corp Stock Research

CERS

2.95USD+0.05(+1.72%)Market Closed

Market Summary

USD2.95+0.05
Market Closed
1.72%

CERS Alerts

CERS Stock Price

CERS RSI Chart

CERS Valuation

Market Cap

522.8M

Price/Earnings (Trailing)

-12.22

Price/Sales (Trailing)

3.91

EV/EBITDA

-14.48

Price/Free Cashflow

-18.93

CERS Price/Sales (Trailing)

CERS Profitability

EBT Margin

-26.29%

Return on Equity

-62.39%

Return on Assets

-19.62%

Free Cashflow Yield

-5.28%

CERS Fundamentals

CERS Revenue

Revenue (TTM)

159.5M

CERS Earnings

Earnings (TTM)

-42.8M

Earnings Y/Y

-49.4%

Earnings Q/Q

-60.62%

Price Action

52 Week Range

2.365.95
(Low)(High)

Last 7 days

3.6%

Last 30 days

-3.6%

Last 90 days

-29.4%

Trailing 12 Months

-40.2%

CERS Financial Health

Current Ratio

1.45

CERS Investor Care

Shares Dilution (1Y)

3.10%

Diluted EPS (TTM)

-0.24

Peers (Alternatives to Cerus)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
SYK
104.1B
18.4B
 2.26% 8.00%
44.16
5.64
 7.84% 18.25%
ISRG
84.2B
6.2B
 -4.47% -13.27%
63.66
13.53
 8.97% -22.43%
BSX
69.1B
12.7B
 0.59% 12.45%
99.06
5.45
 6.68% -32.95%
BDX
67.4B
19.0B
 -5.16% -6.78%
41.86
3.55
 -0.43% -8.78%
EW
49.8B
5.4B
 2.41% -25.12%
32.74
9.26
 2.86% 1.25%
MID-CAP
SWAV
7.2T
489.7M
 9.34% 31.15%
82.2K
16.8K
 106.51% 2464.23%
PEN
10.2B
847.1M
 -3.64% 34.52%
-5.1K
12.05
 13.32% -137.89%
GMED
5.2B
1.0B
 -11.64% -20.31%
30.19
5.09
 6.76% 24.45%
IRTC
3.5B
410.9M
 4.51% -3.13%
-29.82
8.43
 27.29% -14.60%
TNDM
2.7B
801.2M
 1.13% -58.87%
-28.25
3.34
 14.00% -707.69%
SMALL-CAP
SILK
1.7B
138.6M
 -15.68% 29.18%
-30.43
12.07
 36.62% -10.44%
ATEC
1.6B
350.9M
 10.38% 49.06%
-10.84
4.7
 44.26% -5.42%
AVNS
1.3B
820.0M
 -8.35% -12.22%
25.89
1.59
 10.13% 701.59%
CSII
828.4M
239.8M
 0.30% 1.49%
-21.88
3.45
 -4.74% -31.15%

Financials for Cerus

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q4
Revenue26.1%160127121116114
Operating Expenses-145----
  S&GA Expenses-81.00----
Earnings Before Taxes--54.06----
Interest Expenses-5.00----
Net Income--54.37----
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.2%218215216222237
  Current Assets3.3%170165165173187
    Cash Equivalents29.4%37.0029.0032.0038.0049.00
  Inventory2.4%29.0028.0028.0029.0027.00
  Net PPE3.0%11.0011.0011.0012.0012.00
  Goodwill0%1.001.001.001.001.00
Liabilities5.8%150141140141152
  Current Liabilities23.2%11795.0079.0067.0079.00
Shareholder's Equity-6.2%69.0073.0077.0080.0085.00
  Retained Earnings-1.4%-1,007-993-985-976-964
  Additional Paid-In Capital0.7%1,0771,0701,0631,0571,049
Shares Outstanding0.2%177177174174-
Minority Interest-0.1%1.001.001.001.001.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-2.1%-25,615-25,081-29,605-37,923-33,922
  Share Based Compensation3.0%24,45623,73923,86324,66423,571
Cashflow From Investing121.6%8,464-39,209-15,414-82.0012,688
Cashflow From Financing-73.5%4,19215,83319,33019,25534,294

Risks for CERS

What is the probability of a big loss on CERS?

100%

Probability that Cerus stock will be more than 20% underwater in next one year

84.6%

Probability that Cerus stock will be more than 30% underwater in next one year.

48.5%

Probability that Cerus stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CERS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Cerus was unfortunately bought at previous high price.

Drawdowns

Returns for CERS

Cumulative Returns on CERS

-4.3%

10-Year Cumulative Returns

-9.4%

7-Year Cumulative Returns

-12.8%

5-Year Cumulative Returns

-11.0%

3-Year Cumulative Returns

What are the long-term rolling returns for CERS?

FIve years rolling returns for Cerus.

Annualized Returns

Which funds bought or sold CERS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
325
5,325
 -%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-80.63
-290,843
71,157
 -%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-1.08
1,000
94,000
 -%
2023-02-28
Voya Investment Management LLC
reduced
-17.99
-963,408
4,751,590
 0.01%
2023-02-27
Parallax Volatility Advisers, L.P.
sold off
-100
-175,000
-
 -%
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-8,000
-
 -%
2023-02-15
Pier Capital, LLC
reduced
-27.57
-1,291,760
3,572,240
 0.58%
2023-02-15
State of Wyoming
added
215
136,440
199,440
 0.07%
2023-02-15
Steward Partners Investment Advisory, LLC
reduced
-14.16
-2,881
22,119
 -%
2023-02-15
MetLife Investment Management, LLC
reduced
-10.22
-30,134
302,866
 -%

1–10 of 43

Latest Funds Activity

Are funds buying CERS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CERS
No. of Funds

CERS Alerts

Cerus News

Defense World

44157 Shares in Cerus Co. (NASDAQ:CERS) Acquired by MQS ....

Defense World,
14 hours ago

Marketing Sentinel

Cerus Corporation (NASDAQ:CERS) Is Worth Considering At $2.95.

Marketing Sentinel,
36 hours ago

Stocks Register

The Next Few Weeks Are A Good Time To Consider Cerus ....

Stocks Register,
2 days ago

Defense World

Baird Financial Group Inc. Sells 2391 Shares of Norfolk Southern Co ....

Defense World,
3 days ago

Defense World

Bilibili (NASDAQ:BILI) Shares Gap Up to $19.73.

Defense World,
3 days ago

Defense World

Short Interest in JELD-WEN Holding, Inc. (NYSE:JELD) Decreases ....

Defense World,
3 days ago

MarketBeat

Engineers Gate Manager LP Purchases 42432 Shares of Cerus Co ....

MarketBeat,
5 days ago

Seeking Alpha

UFP Technologies, Inc. (UFPT) Stock Price Today, Quote & News.

Seeking Alpha,
5 days ago

Defense World

LXB Retail Properties (LON:LXB) Share Price Passes Below Two ....

Defense World,
7 days ago

MarketBeat

Pier Capital LLC Sells 380161 Shares of Cerus Co. (NASDAQ:CERS).

MarketBeat,
8 days ago

TipRanks

‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks ....

TipRanks,
8 days ago

Defense World

Comparing NeuroMetrix (NASDAQ:NURO) & Cerus (NASDAQ:CERS).

Defense World,
9 days ago

The News Heater

Cerus Corporation (CERS) Stock: A Look at the Monthly Trend.

The News Heater,
10 days ago

MZP News

There is no shortage of investors who are bullish on Cerus ....

MZP News,
12 days ago

Stocks Register

Investors Profit From 3.93% Gain In Cerus Corporation (NASDAQ ....

Stocks Register,
12 days ago

ETF Daily News

Cerus Co. (NASDAQ:CERS) Shares Acquired by MetLife Investment ....

ETF Daily News,
14 days ago

Schedule 13G FIlings of Cerus

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
baker bros. advisors lp
9.1%
16,067,558
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
4.04%
7,171,280
SC 13G/A
Feb 10, 2023
ark investment management llc
10.11%
17,943,131
SC 13G/A
Feb 10, 2023
ark investment management llc
8.94%
15,863,384
SC 13G/A
Feb 09, 2023
vanguard group inc
6.14%
10,900,422
SC 13G/A
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
4.04%
7,171,280
SC 13G/A
Jan 31, 2023
blackrock inc.
7.1%
12,594,054
SC 13G/A
Jan 09, 2023
primecap management co/ca/
4.99%
8,849,600
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
6.69%
11,529,716
SC 13G/A
Feb 10, 2022
primecap management co/ca/
5.64%
9,722,300
SC 13G/A

CERS Fair Value

Cerus fair value in different scenarios

The table shows the Fair Value estimates for Cerus for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

0.21

-92.88%

0.37

-87.46%

0.72

-75.59%

1.36

-53.90%

2.11

-28.47%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Cerus Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Cerus

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 10, 2023
8-K
Current Report
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading

Latest Insider Trading transactions for CERS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Menard Chrystal
sold
-43,310
2.8
-15,468
chief legal officer
2023-03-13
CORASH LAURENCE M
sold
-42,957
2.8
-15,342
chief scientific officer
2023-03-13
Benjamin Richard J
sold
-70,781
2.79184
-25,353
chief medical officer
2023-03-13
Moore Carol
sold
-36,618
2.8
-13,078
svp reg. & quality
2023-03-13
Green Kevin Dennis
sold
-48,056
2.8
-17,163
chief financial officer
2023-03-13
Greenman William Mariner
sold
-169,344
2.8
-60,480
president and ceo
2023-03-13
Jayaraman Vivek K
sold
-70,996
2.8
-25,356
chief operating officer
2023-03-12
Greenman William Mariner
acquired
-
-
172,192
president and ceo
2023-03-12
Moore Carol
acquired
-
-
35,127
svp reg. & quality
2023-03-12
Jayaraman Vivek K
acquired
-
-
69,200
chief operating officer

1–10 of 50

About Cerus

William M. Greenman
www.cerus.com
290
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CERS Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue$ 188,315$ 159,518$ 114,249
Operating expenses:   
Research and development64,10763,69164,410
Selling, general and administrative83,33581,28867,015
Total operating expenses147,442144,979131,425
Loss from operations(34,081)(48,936)(58,333)
Non-operating expense, net:   
Foreign exchange (loss) gain(690)(572)793
Interest expense(5,831)(4,923)(3,746)
Other (expense) income, net(1,735)3741,713
Total non-operating expense, net(8,256)(5,121)(1,240)
Loss before income taxes(42,337)(54,057)(59,573)
Provision for income taxes488319284
Net loss(42,825)(54,376)(59,857)
Net loss attributable to noncontrolling interest(46)(2) 
Net loss attributable to Cerus Corporation$ (42,779)$ (54,374)$ (59,857)
Net loss per share attributable to Cerus Corporation   
Basic$ (0.24)$ (0.32)$ (0.37)
Diluted$ (0.24)$ (0.32)$ (0.37)
Weighted average shares outstanding:   
Basic176,545171,279163,949
Diluted176,545171,279163,949
Product   
Revenue$ 162,048$ 130,859$ 91,920
Cost of revenue74,95463,47541,157
Gross profit87,09467,38450,763
Government Contract   
Revenue$ 26,267$ 28,659$ 22,329

CERS Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 35,585$ 48,759
Short-term investments66,56980,600
Accounts receivable34,42625,129
Current inventories, net29,00326,793
Prepaid and other current assets4,5615,821
Total current assets170,144187,102
Non-current assets:  
Property and equipment, net10,96912,208
Operating lease right-of-use assets12,51212,971
Goodwill1,3161,316
Restricted cash1,7732,285
Other assets21,37821,617
Total assets218,092237,499
Current liabilities:  
Accounts payable33,00235,608
Accrued liabilities25,20325,673
Debt – current56,15914,697
Operating lease liabilities – current2,1051,905
Deferred product revenue589673
Total current liabilities117,05878,556
Non-current liabilities:  
Debt – non-current13,64454,724
Operating lease liabilities – non-current15,32916,260
Other non-current liabilities3,4992,342
Total liabilities149,530151,882
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized, issuable in series; zero shares issued and outstanding at December 31, 2022 and 2021, respectively
Common stock, $0.001 par value; 400,000 shares authorized; 177,581 and 173,670 shares issued and outstanding at December 31, 2022 and 2021, respectively177174
Additional paid-in capital1,077,3411,048,936
Accumulated other comprehensive loss(2,787)(149)
Accumulated deficit(1,007,121)(964,342)
Total Cerus Corporation stockholders' equity67,61084,619
Noncontrolling interest952998
Total liabilities and stockholders' equity$ 218,092$ 237,499